サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1392855

肺動脈性肺高血圧症（PAH）の世界市場レポート 2024年

Pulmonary Arterial Hypertension Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肺動脈性肺高血圧症（PAH）の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

肺動脈性肺高血圧症（PAH）市場規模は近年力強く成長しています。2023年の78億5,000万米ドルから2024年にはCAGR 9.2％で85億7,000万米ドルに成長します。過去の期間に見られた成長は、肺動脈性肺高血圧症（PAH）（PAH）に対する認識と診断の増加、医療費の増加、高齢化人口の増加、肺動脈性肺高血圧症（PAH）に対する治療選択肢の拡大、肺高血圧症に焦点を当てた研究開発活動の増加といった要因に起因しています。これらの要因が総合的に肺動脈性肺高血圧症（PAH）の理解と管理の進歩に寄与し、診断と治療選択肢の改善につながっています。

2023年の肺動脈性肺高血圧症（PAH）市場で最大の地域は北米でした。肺動脈性肺高血圧症（PAH）市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 肺動脈性肺高血圧症（PAH）市場の特徴

第3章 肺動脈性肺高血圧症（PAH）市場の動向と戦略

第4章 肺動脈性肺高血圧症（PAH）市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の肺動脈性肺高血圧症（PAH）市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033F

第6章 肺動脈性肺高血圧症（PAH）市場セグメンテーション

  • 世界の肺動脈性肺高血圧症（PAH）市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドセリン受容体拮抗薬（ERA）
  • PDE-5阻害剤
  • プロスタサイクリンおよびプロスタサイクリン類似体
  • SGC刺激装置
  • 世界の肺動脈性肺高血圧症（PAH）市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028F、2033F
  • 経口
  • 静脈内/皮下
  • 吸入
  • 世界の肺動脈性肺高血圧症（PAH）市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 小売
  • オンライン

第7章 肺動脈性肺高血圧症（PAH）市場の地域別・国別分析

  • 世界の肺動脈性肺高血圧症（PAH）市場、地域別、実績および予測、2018-2023、2023-2028F、2033F
  • 世界の肺動脈性肺高血圧症（PAH）市場、国別、実績および予測、2018-2023、2023-2028F、2033F

第8章 アジア太平洋の肺動脈性肺高血圧症（PAH）市場

  • 概要
  • 地域情報、COVID-19症の影響、市場情報、背景情報、政府の取り組み、規制、規制機関、主要団体、課税額、法人税構造、投資、主要企業
  • 薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第9章 中国の肺動脈性肺高血圧症（PAH）市場

第10章 インドの肺動脈性肺高血圧症（PAH）市場

第11章 日本の肺動脈性肺高血圧症（PAH）市場

第12章 オーストラリアの肺動脈性肺高血圧症（PAH）市場

第13章 インドネシアの肺動脈性肺高血圧症（PAH）市場

第14章 韓国の肺動脈性肺高血圧症（PAH）市場

第15章 西欧の肺動脈性肺高血圧症（PAH）市場

  • 概要
  • 薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第16章 英国の肺動脈性肺高血圧症（PAH）市場

第17章 ドイツの肺動脈性肺高血圧症（PAH）市場

第18章 フランスの肺動脈性肺高血圧症（PAH）市場

第19章 イタリアの肺動脈性肺高血圧症（PAH）市場

第20章 スペインの肺動脈性肺高血圧症（PAH）市場

第21章 東欧の肺動脈性肺高血圧症（PAH）市場

  • 概要
  • 薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第22章 ロシアの肺動脈性肺高血圧症（PAH）市場

第23章 北米の肺動脈性肺高血圧症（PAH）市場

  • 概要
  • 薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第24章 米国の肺動脈性肺高血圧症（PAH）市場

第25章 カナダの肺動脈性肺高血圧症（PAH）市場

第26章 南米の肺動脈性肺高血圧症（PAH）市場

  • 概要
  • 薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第27章 ブラジルの肺動脈性肺高血圧症（PAH）市場

第28章 中東の肺動脈性肺高血圧症（PAH）市場

  • 概要
  • 薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第29章 アフリカの肺動脈性肺高血圧症（PAH）市場

  • 概要
  • 薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第30章 肺動脈性肺高血圧症（PAH）市場の競合情勢と企業プロファイル

  • 肺動脈性肺高血圧症（PAH）市場の競合情勢
  • 肺動脈性肺高血圧症（PAH）市場の企業プロファイル
    • United Therapeutics Corporation
    • Acceleron Pharma Inc.
    • Actelion Pharmaceuticals US Inc.
    • Bayer AG
    • Eli Lilly and Company

第31章 世界の肺動脈性肺高血圧症（PAH）市場の競合ベンチマーキング

第32章 世界の肺動脈性肺高血圧症（PAH）市場の競合ダッシュボード

第33章 肺動脈性肺高血圧症（PAH）市場における主要な合併と買収

第34章 肺動脈性肺高血圧症（PAH）市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10543

“Pulmonary Arterial Hypertension Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary arterial hypertension market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary arterial hypertension? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The pulmonary arterial hypertension market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Class: Endothelin Receptor Antagonists (ERAs); PDE-5 Inhibitors; Prostacyclin and Prostacyclin Analogs; SGC Stimulators
  • 2) By Route of Administration: Oral; Intravenous/ subcutaneous; Inhalational
  • 3) By Distribution channel: Retail; Online
  • Companies Mentioned: United Therapeutics Corporation; Acceleron Pharma Inc.; Actelion Pharmaceuticals US Inc.; Bayer AG; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Pulmonary arterial hypertension refers to a condition characterized by elevated blood pressure in the arteries of the lungs, leading to damage to the right side of the heart and the lung arteries. This long-lasting and incurable condition results in the constriction and rigidity of the walls of the pulmonary arteries. Pulmonary arterial hypertension drugs are designed to address this condition by relaxing the muscles in the blood vessel walls, increasing blood flow through the lungs, or reversing the effects of substances in the blood vessel walls that cause them to narrow.

The main types of drug classes for pulmonary arterial hypertension include endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. Endothelin receptor antagonists (ERAs) are a targeted medication used for treating pulmonary hypertension in patients. Targeted medications aim to reduce the progression of pulmonary hypertension and potentially reverse some of the damage to the heart and lungs. These drugs can be administered through oral, intravenous/subcutaneous, and inhalational modes, and they are distributed through retail and online channels.

The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $7. 85 billion in 2023 to $8. 57 billion in 2024 at a compound annual growth rate (CAGR) of 9. 2%. The growth observed in the historical period can be attributed to factors such as increased awareness and diagnosis of pulmonary arterial hypertension (PAH), a rise in healthcare expenditure, growth in the aging population, expansion of treatment options for pulmonary arterial hypertension, and an increase in research and development activities focused on pulmonary hypertension. These factors have collectively contributed to advancements in the understanding and management of pulmonary arterial hypertension, leading to improved diagnosis and treatment options.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $11. 99 billion in 2028 at a compound annual growth rate (CAGR) of 8. 8%. The anticipated growth in the forecast period can be attributed to the adoption of novel therapies for pulmonary arterial hypertension, an increased focus on early detection and diagnosis, a growing pipeline of drugs and therapies for PAH, the integration of precision medicine in PAH treatment, and the expansion of healthcare infrastructure in emerging markets. Major trends expected in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, and an increased use of combination therapy. These trends reflect the ongoing efforts to enhance treatment options, early intervention, and overall patient care in the field of pulmonary arterial hypertension.

The growth of the pulmonary arterial hypertension market is being propelled by the increasing prevalence of pulmonary arterial hypertension (PAH) disease. The rise in PAH cases and the subsequent hospitalization of patients for treatment are expected to drive the demand for relevant drugs in the forecast period. According to the National Organization for Rare Disorders, Inc., a study suggests that new cases of PAH are estimated to occur in one to two individuals per million annually in the USA, equating to 500-1000 new cases each year, with similar incidence rates expected in Europe.

The pulmonary arterial hypertension market is anticipated to experience growth due to the increasing number of clinical trials for drug development. Clinical trials play a crucial role in assessing the safety, efficacy, and potential side effects of new drugs or treatments in humans. For pulmonary arterial hypertension drug development, these trials hold the promise of leading to the creation of more effective treatments, thereby improving the quality of life, enhancing safety and efficacy, providing early access, and identifying cost-effective treatments. Xtalks reported in May 2023 that there were 452,604 registered clinical studies on ClinicalTrials. gov, with 64,838 actively seeking participants-an increase of 365,000 registered trials in 2021. Hence, the surge in clinical trials for drug development is a key driver for the pulmonary arterial hypertension market.

Technological advancements stand out as significant trends gaining traction in the pulmonary arterial hypertension market. Companies in the pulmonary arterial hypertension drug sector are actively involved in developing new medicines to enhance and treat these diseases. For example, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease in April 2021. Tyvaso, an inhalation solution, aims to help patients improve exercise abilities, alleviate breathing difficulties, increase tolerance for exertion, and reduce mortality rates.

Major players in the pulmonary arterial hypertension market are strategically focusing on product approvals, such as Tyvaso, to drive revenues. Tyvaso (treprostinil) inhalation solution is prescribed to treat patients with interstitial lung disease (PH-ILD; WHO Group 3) and pulmonary hypertension, enhancing their activity capacity. In April 2021, United Therapeutics Corporation received FDA approval for Tyvaso, marking a significant advancement in treatment for individuals with PH-ILD.

In September 2021, Merck Group, a German-based multinational science and technology company specializing in healthcare and life sciences solutions, acquired Acceleron Pharma for $11 billion. This acquisition positions Merck at the forefront of rare disease-focused companies, providing ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication. Acceleron Pharma, a US-based company, is dedicated to researching, developing, and commercializing therapies for critical and uncommon conditions like pulmonary arterial hypertension.

Major companies operating in the in the pulmonary arterial hypertension market report are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

North America was the largest region in the pulmonary arterial hypertension market in 2023. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Pulmonary Arterial Hypertension Market Characteristics

3. Pulmonary Arterial Hypertension Market Trends And Strategies

4. Pulmonary Arterial Hypertension Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pulmonary Arterial Hypertension Market Size and Growth

  • 5.1. Global Pulmonary Arterial Hypertension Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pulmonary Arterial Hypertension Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pulmonary Arterial Hypertension Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pulmonary Arterial Hypertension Market Segmentation

  • 6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Endothelin Receptor Antagonists (ERAs)
  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • 6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Intravenous/ subcutaneous
  • Inhalational
  • 6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Retail
  • Online

7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

  • 7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pulmonary Arterial Hypertension Market

  • 8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8. 4. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pulmonary Arterial Hypertension Market

  • 9.1. China Pulmonary Arterial Hypertension Market Overview
  • 9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9. 4. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pulmonary Arterial Hypertension Market

  • 10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pulmonary Arterial Hypertension Market

  • 11.1. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pulmonary Arterial Hypertension Market

  • 12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pulmonary Arterial Hypertension Market

  • 13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pulmonary Arterial Hypertension Market

  • 14.1. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pulmonary Arterial Hypertension Market

  • 15.1. Western Europe Pulmonary Arterial Hypertension Market Overview
  • 15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15. 4. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pulmonary Arterial Hypertension Market

  • 16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pulmonary Arterial Hypertension Market

  • 17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pulmonary Arterial Hypertension Market

  • 18. 5. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 6. France Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 7. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pulmonary Arterial Hypertension Market

  • 19. 9. Italy Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pulmonary Arterial Hypertension Market

  • 20.13. Spain Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pulmonary Arterial Hypertension Market

  • 21.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview
  • 21.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21. 4. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pulmonary Arterial Hypertension Market

  • 22.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pulmonary Arterial Hypertension Market

  • 23.1. North America Pulmonary Arterial Hypertension Market Overview
  • 23.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23. 4. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pulmonary Arterial Hypertension Market

  • 24.1. USA Pulmonary Arterial Hypertension Market Overview
  • 24.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24. 4. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pulmonary Arterial Hypertension Market

  • 25.1. Canada Pulmonary Arterial Hypertension Market Overview
  • 25.2. Canada Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25. 4. Canada Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pulmonary Arterial Hypertension Market

  • 26.1. South America Pulmonary Arterial Hypertension Market Overview
  • 26.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26. 4. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pulmonary Arterial Hypertension Market

  • 27.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pulmonary Arterial Hypertension Market

  • 28.1. Middle East Pulmonary Arterial Hypertension Market Overview
  • 28.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28. 4. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pulmonary Arterial Hypertension Market

  • 29.1. Africa Pulmonary Arterial Hypertension Market Overview
  • 29.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29. 4. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

  • 30.1. Pulmonary Arterial Hypertension Market Competitive Landscape
  • 30.2. Pulmonary Arterial Hypertension Market Company Profiles
    • 30.2.1. United Therapeutics Corporation
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1. 4. Financial Performance
    • 30.2.2. Acceleron Pharma Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2. 4. Financial Performance
    • 30.2.3. Actelion Pharmaceuticals US Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3. 4. Financial Performance
    • 30.2. 4. Bayer AG
      • 30.2. 4.1. Overview
      • 30.2. 4.2. Products and Services
      • 30.2. 4.3. Strategy
      • 30.2. 4. 4. Financial Performance
    • 30.2. 5. Eli Lilly and Company
      • 30.2. 5.1. Overview
      • 30.2. 5.2. Products and Services
      • 30.2. 5.3. Strategy
      • 30.2. 5. 4. Financial Performance

31. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking

32. Global Pulmonary Arterial Hypertension Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

34. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis

  • 34.1 Pulmonary Arterial Hypertension Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Pulmonary Arterial Hypertension Market In 2028 - Segments Offering Most New Opportunities
  • 34. 3 Pulmonary Arterial Hypertension Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35. 4. Research Inquiries
  • 35. 5. The Business Research Company
  • 35. 6. Copyright And Disclaimer